Novo Nordisk Bets on Rebranding, Pipeline Deals to Move Past Semaglutide Era

Novo Nordisk rebrands as Novo and signs a deal worth up to USD 1.4 billion, as its stock falls 15% this year ahead of Monday's strategy day.

Ahead of its capital markets day in London, Novo Nordisk is racing to convince investors that its next chapter does not hinge on a single blockbuster. The Danish drugmaker has spent the past two weeks rolling out a rebranding, a billion-dollar licensing deal and fresh regulatory wins, all while absorbing clinical setbacks that have kept its share price under water.

The stock has shed 15 percent since the start of the year, closing Friday at EUR 37.58. Management will use Monday's investor gathering to lay out an updated corporate strategy, with the emphasis on long-term prospects beyond semaglutide.

A new name, a new playbook

Chief executive Mike Doustdar rallied staff last Tuesday around a sharper customer focus, aiming to recapture momentum in the obesity business. As part of that push, the company will go to market simply as "Novo" in day-to-day operations, though the legal entity Novo Nordisk A/S stays as is. A revised set of guiding principles, branded "The Novo Way," puts customer orientation, competitiveness, clarity and integrity at the center.

The strategic reset arrives against a backdrop of analyst caution. On September 11, Morgan Stanley downgraded the shares from "Equal-weight" to "Underweight," citing softer medium-term growth and patent risks that bite after 2030. One source put the price target at 250 Danish kroner, implying downside of more than 10 percent; another reported a target of USD 40.00. Either way, the bank sees limited room for major surprises at Monday's event, expecting management instead to reaffirm its vision for the oral obesity market and showcase progress in MASH and chronic kidney disease.

Deals and approvals offset pipeline stumbles

Novo moved Thursday to broaden its portfolio, signing a licensing and development agreement with Orbis Medicines covering oral cardiometabolic therapies. The pact carries a potential total value of up to USD 1.4 billion, and Novo is taking a strategic stake in the privately held partner.

Regulatory news followed on Friday, when the European Medicines Agency's Committee for Medicinal Products for Human Use backed approval of Sogroya (somapacitan) for children with idiopathic short stature in Europe. The once-weekly therapy now awaits a final European Commission decision, expected during 2026.

Those gains came alongside disappointing trial news. According to a Reuters report, the company halted two studies of ziltivekimab in heart failure on September 7, after an independent data monitoring committee concluded that a divergent result from an earlier failed late-stage trial was unlikely. A separate post-heart-attack study continues, with data anticipated in the first half of 2027.

Early-stage data and buybacks round out the picture

On the clinical front, Novo reported positive results in early September from the Phase 3 STEP Young trial. In children aged six to under twelve with obesity, weekly semaglutide combined with lifestyle changes produced a statistically superior reduction in body mass index versus placebo over 68 weeks. Among treated children, 40.4 percent brought their BMI below the obesity threshold.

Meanwhile, the company's capital return program keeps running. Between February 4 and September 11, Novo repurchased 33,084,179 of its own B shares for roughly DKK 9.3 billion, at an average price of DKK 281.89 per share.

Monday's strategy day now becomes the stage on which management must show how it intends to protect future value creation as semaglutide's patent clock ticks down.